Fibroblast growth factor 23 in chronic kidney disease: Bridging the gap between bone mineral metabolism and Left Ventricular Hypertrophy

Blood Purification

Volumn 31, Issue 1-3, 2011, Pages 26-32

  Canziani, M E F ^a   Tomiyama, C ^a   Higa, A ^a   Draibe, S A ^a   Carvalho, A B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bone metabolism; Chronic kidney disease; Fibroblast growth factor 23 (FGF23); Hyperparathyroidism; Inflammation; Left ventricular hypertrophy

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 23; GLUCOSE; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHORUS; TRIACYLGLYCEROL; VITAMIN D;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; BONE MINERAL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CONFERENCE PAPER; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART VENTRICLE SIZE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PHOSPHORUS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC;

EID: 78649698386     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321368     Document Type: Conference Paper

References (38)

1. Foley RN, Parfrey PS, Sarnak MJ: Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9:S16-S23.
2. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
3. Kimura T, Iio K, Obi Y, Hayashi T: Left ventricular hypertrophy in predialysis chronic kidney disease: impact of cardiomuscular stress markers. Nippon Jinzo Gakkai Shi 2007; 49: 1007-1013.
4. Paoletti E, Bellino D, Cassottana P, Rolla D, Cannella G: Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 2005; 46: 320-327.
5. Yilmaz BA, Mete T, Dincer I, Kutlay S, Sengül S, Keven K, Ertürk S: Predictors of left ventricular hypertrophy in patients with chronic kidney disease. Ren Fail 2007; 29: 303-307.
6. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
7. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS: Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. Kidney Int 2004; 65: 1492-1498. (Pubitemid 38406992)
8. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767.
9. Middleton RJ, Parfrey PS, Foley RN: Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12: 1079-1084.
10. Cottone S, Nardi E, Mulè G, Vadalà A, Lorito MC, Riccobene R, Palermo A, Arsena R, Guarneri M, Cerasola G: Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol 2007; 67: 209-216.
11. Achinger SG, Ayus JC: Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? J Am Soc Nephrol 2006; 17(suppl 3):S255-S261.
12. Hsu HJ, Wu MS: Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci 2009; 337: 116-122.
13. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552.
14. Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton P, Krumholz HM, LaRosa J, Ockene IS, Pearson TA, Reed J, Washington R, Smith SCJ: Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. Circulation 1998; 97: 1876-1887.
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). Ann Intern Med 2009; 150: 604-612.
16. National Kidney Foundation: K/DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39:S46-S103.
17. KDIGO Clinical Practice Guideline for the Diagnosis: Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76(suppl 113):SVII.
18. Sahn DJ, DeMaria A, Kisslo A, et al: Recommendations regarding quantification in mmode echocardiography: results of a survey of echocardiography measurements. Circulation 1978; 58: 1072-1086.
19. Savage DD, Garrison RY, Kannel WB, Levy D, Anderson SJ, Stokes J III, Feinleib M, Castelli WP: The spectrum of left ventricular hypertrophy in a general population sample: the Framingham study. Circulation 1987; 75: 26-33.
20. Fitzpatrick LA, Bilezikian JP, Silverberg SJ: Parathyroid hormone and the cardiovascular system. Curr Osteoporos Rep 2008; 6: 77-83.
21. Mall G, Rambausek M, Neumeister A, Kollmar S, Vetterlein F, Ritz E: Myocardial interstitial fibrosis in experimental uremia - implication for cardiac compliance. Kidney Int 1998; 33: 804-811.
22. Lowik CW, van der Pluijm G, Bloys H, Hoekman K, Bijvoet OL, Aarden LA, Papapoulos SE: Parathyroid hormone (PTH) and PTHlike protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 1989; 162: 1546-1552.
23. Mitnick MA, Grey A, Masiukiewicz U, Bartkiewicz M, Rios-Velez L, Friedman S, Xu L, Horowitz MC, Insogna K: Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol Endocrinol Metab 2001; 280:E405-E412.
24. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li RK, Mickle DA, Verma S: C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-1790.
25. London GM, Marchais SJ, Guerin AP, Metivier F, Adda H: Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 1713-1724.
26. El-Abbadi MM, Pai AS, Leaf EM, Yang HY, Bartley BA, Quan KK, Ingalls CM, Liao HW, Giachelli CM: Phosphate feeding induces arterial medial calcification in uremic mice: role of serum phosphorus, fibroblast growth factor-23, and osteopontin. Kidney Int 2009; 75: 1297-1307.
27. Neves KR, Graciolli FG, dos Reis LM, Pasqualucci CA, Moysés RM, Jorgetti V: Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. Kidney Int 2004; 66: 2237-2244.
28. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885.
29. Seiler S, Heine GH, Fliser D: Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int 2009; 76:S34-S42.
30. Ix JH, Shlipak MG, Wassel CL, Whooley MA: Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010; 25: 993-997.
31. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C: High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009; 24: 2792-2796.
32. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
33. Tomita Y, Kusama Y, Seino Y, Munakata K, Kishida H, Hayakawa H: Increased accumulation of acidic fibroblast growth factor in left ventricular myocytes of patients with idiopathic cardiomyopathy. Am Heart J 1997; 134: 779-786.
34. Vatner SF: FGF induces hypertrophy and angiogenesis in hibernating myocardium. Circ Res 2005; 96: 705-707.
35. Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, Yasui K, Lee JK, Kamiya K, Kitaichi K, Yamamoto K, Ito M, Kondo T, Iino S, Inden Y, Hirai M, Murohara T, Kodama I, Nabeshima Y: Sinoatrial node dysfunction and early unexpected death of mice with a defect of Klotho gene expression. Circulation 2004; 109: 1776-1782.
36. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE: Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009; 207: 546-551.
37. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM: Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291.
38. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD: Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 2010; 5: 110-116.